Andexxa (Ondexxya) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to widespread use of factor xa inhibitors, emergency bleeding incidents, regulatory approval of reversal agents, hospital critical care demand, aging population.

The growth in the forecast period can be attributed to growth in cardiovascular disease prevalence, increased anticoagulant prescriptions, trauma care expansion, improved emergency protocols, rising surgical interventions. Major trends in the forecast period include rising need for anticoagulant reversal, growth in emergency bleeding management, hospital centered critical care therapies, increased use of factor xa inhibitors, focus on rapid hemostasis solutions.

The rising prevalence of bleeding disorders is expected to drive the growth of the andexxa (ondexxya) market in the coming years. Bleeding disorders are a group of medical conditions that affect the blood’s ability to clot normally, resulting in excessive or prolonged bleeding. The increase in bleeding disorders is attributed to improved diagnostic capabilities, greater disease awareness, genetic factors, and an aging population, all of which contribute to higher detection and recognition rates. Andexxa (Ondexxya) plays a critical role in managing bleeding disorders by rapidly reversing the anticoagulant effects of factor Xa inhibitors, thereby preventing life-threatening bleeding in emergency situations. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,797 patients living with von Willebrand disease (VWD) in 2023-2024, an increase from 2,669 patients in 2022-2023. Therefore, the growing prevalence of bleeding disorders is driving the growth of the andexxa (ondexxya) market.

The expanding geriatric population is expected to propel the growth of the andexxa (ondexxya) market going forward. The geriatric population includes individuals aged 65 years and older, who commonly experience age-related health challenges such as chronic illnesses, reduced mobility, and cognitive decline. This population segment is growing worldwide due to rising life expectancy and improvements in healthcare systems. Andexxa (Ondexxya) is particularly beneficial for elderly patients as it helps reverse bleeding caused by anticoagulant therapies, which are more frequently prescribed to older adults for conditions such as atrial fibrillation. For instance, in October 2022, according to the World Health Organization (WHO), a Switzerland-based international public health agency, one in six people globally is expected to be aged 60 years or older by 2030, with the number projected to reach 2.1 billion people aged 60 and above by 2050. Therefore, the growth of the geriatric population is driving the expansion of the andexxa (ondexxya) market.

Leading companies operating in the andexxa (ondexxya) market are increasingly focused on developing advanced anticoagulant reversal therapies to improve patient safety during critical bleeding events. Reversal therapy refers to targeted treatments designed to neutralize the effects of anticoagulant medications, quickly restoring normal clotting function and reducing the risk of fatal bleeding. For instance, in January 2024, AstraZeneca India received approval from the CDSCO to import and market andexanet alfa for the treatment of life-threatening or uncontrolled bleeding caused by factor Xa inhibitors such as apixaban and rivaroxaban. This newly approved therapy involves an initial intravenous bolus administered over 15-30 minutes, followed by a continuous infusion lasting two hours. Andexanet alfa has demonstrated safety and efficacy in clinical studies involving major bleeding, enables the early resumption of anticoagulation therapy after bleeding events, is well tolerated, and addresses a significant unmet need among patients receiving novel oral anticoagulants.

Major companies operating in the andexxa (ondexxya) market are AstraZeneca Plc.

North America was the largest region in the andexxa (ondexxya) market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the andexxa (ondexxya) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the andexxa (ondexxya) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the andexxa market by increasing costs for recombinant protein production materials and advanced biologics processing equipment. These impacts are most evident in hospital pharmacies and emergency departments across europe and asia pacific. Higher import duties have added financial pressure on critical care drug inventories. Supply chain efficiency has also been influenced by customs and regulatory delays. At the same time, tariffs are promoting domestic biologics manufacturing and improving regional supply security.

The andexxa (ondexxya) market research report is one of a series of new reports that provides andexxa (ondexxya) market statistics, including andexxa (ondexxya) industry global market size, regional shares, competitors with a andexxa (ondexxya) market share, detailed andexxa (ondexxya) market segments, market trends and opportunities, and any further data you may need to thrive in the andexxa (ondexxya) industry. This andexxa (ondexxya) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Andexxa (Ondexxya) is a reversal agent used to neutralize the anticoagulant effects of certain blood thinners, specifically factor Xa inhibitors such as rivaroxaban (Xarelto) and apixaban (Eliquis). It is administered in situations involving life-threatening or uncontrolled bleeding or when rapid reversal of anticoagulation is required.

The primary indication types for andexxa (ondexxya) include reversal of bleeding associated with factor Xa inhibitors, acute major bleeding episodes, and use during emergency surgeries or procedures. Factor Xa inhibitors are anticoagulants that reduce blood clot formation, but their effects may need to be counteracted in cases of excessive bleeding. The therapy is distributed through multiple channels, including hospital pharmacies and specialty pharmacies, and is used by adult, geriatric, and pediatric patient populations.

The andexxa (ondexxya) market consists of sales of anticoagulant reversal agents, factor xa inhibitors, hemostatic agents and blood clotting factor concentrates. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.